tiprankstipranks
Trending News
More News >
Ascentage Pharma Group International Unsponsored ADR (AAPG)
:AAPG
US Market
Advertisement

Ascentage Pharma Group International Unsponsored ADR (AAPG) Price & Analysis

Compare
15 Followers

AAPG Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Hospital InclusionThe number of hospitals with Olver included in their formulary has increased significantly, boosting potential sales.
Revenue GrowthOlver recorded significant revenue growth, surpassing last year's revenue due to NRDL's coverage inclusion.
Bears Say
Regulatory ApplicationLisaftoclax missed the deadline to file for NRDL application, though there is confidence in its strategic opportunities.

Ascentage Pharma Group International Unsponsored ADR News

AAPG FAQ

What was Ascentage Pharma Group International Unsponsored ADR’s price range in the past 12 months?
Ascentage Pharma Group International Unsponsored ADR lowest stock price was $16.50 and its highest was $48.45 in the past 12 months.
    What is Ascentage Pharma Group International Unsponsored ADR’s market cap?
    Ascentage Pharma Group International Unsponsored ADR’s market cap is $4.26B.
      When is Ascentage Pharma Group International Unsponsored ADR’s upcoming earnings report date?
      Ascentage Pharma Group International Unsponsored ADR’s upcoming earnings report date is Apr 01, 2026 which is in 220 days.
        How were Ascentage Pharma Group International Unsponsored ADR’s earnings last quarter?
        Ascentage Pharma Group International Unsponsored ADR released its earnings results on Aug 20, 2025. The company reported -$0.964 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.964.
          Is Ascentage Pharma Group International Unsponsored ADR overvalued?
          According to Wall Street analysts Ascentage Pharma Group International Unsponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Ascentage Pharma Group International Unsponsored ADR pay dividends?
            Ascentage Pharma Group International Unsponsored ADR does not currently pay dividends.
            What is Ascentage Pharma Group International Unsponsored ADR’s EPS estimate?
            Ascentage Pharma Group International Unsponsored ADR’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Ascentage Pharma Group International Unsponsored ADR have?
            Ascentage Pharma Group International Unsponsored ADR has 92,963,370 shares outstanding.
              What happened to Ascentage Pharma Group International Unsponsored ADR’s price movement after its last earnings report?
              Ascentage Pharma Group International Unsponsored ADR reported an EPS of -$0.964 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.059%.
                Which hedge fund is a major shareholder of Ascentage Pharma Group International Unsponsored ADR?
                Currently, no hedge funds are holding shares in AAPG

                Ascentage Pharma Group International Unsponsored ADR Stock Smart Score

                3
                Underperform
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Fundamentals

                Return on Equity
                -161.90%
                Trailing 12-Months
                Asset Growth
                -0.59%
                Trailing 12-Months

                Company Description

                Ascentage Pharma Group International Unsponsored ADR

                Ascentage Pharma Group International Unsponsored ADR (AAPG) is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of cancer, hepatitis B, and age-related diseases. The company operates primarily in the oncology and antiviral sectors, leveraging its proprietary drug development platform to create targeted therapeutics that address unmet medical needs. Ascentage Pharma's core products include novel small molecules designed to inhibit key regulatory proteins involved in tumor growth and viral replication.

                Ascentage Pharma Group International Unsponsored ADR (AAPG) Earnings & Revenues

                AAPG Stock 12 Month Forecast

                Average Price Target

                $38.00
                ▼(-20.67% Downside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","39":"$39","21.75":"$21.8","27.5":"$27.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,21.75,27.5,33.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.2,37.261538461538464,37.323076923076925,37.38461538461539,37.44615384615385,37.50769230769231,37.56923076923077,37.63076923076923,37.69230769230769,37.753846153846155,37.815384615384616,37.87692307692308,37.93846153846154,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.2,37.261538461538464,37.323076923076925,37.38461538461539,37.44615384615385,37.50769230769231,37.56923076923077,37.63076923076923,37.69230769230769,37.753846153846155,37.815384615384616,37.87692307692308,37.93846153846154,{"y":38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.2,37.261538461538464,37.323076923076925,37.38461538461539,37.44615384615385,37.50769230769231,37.56923076923077,37.63076923076923,37.69230769230769,37.753846153846155,37.815384615384616,37.87692307692308,37.93846153846154,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.25,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.25,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.25,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.25,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.25,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.68,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.03,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                Protagonist Therapeutics
                Crinetics Pharmaceuticals
                Immunovant
                Kymera Therapeutics
                MoonLake Immunotherapeutics

                Ownership Overview

                0.23%99.75%
                Insiders
                0.23% Other Institutional Investors
                99.75% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis